ECTRIMS 2022 | Strategies to reduce polypharmacy in multiple sclerosis

Anibal Chertcoff, MD, PhD, The University of British Columbia, Vancouver, Canada, outlines the methods to alleviate the risk of polypharmacy in patients with multiple sclerosis. Neurologists should consider the significance of polypharmacy and review the patient’s medications yearly to ensure rational prescribing, thereby preventing therapeutic inertia. Dr Chertcoff points out the need to consider non-pharmacological therapies over pharmacological treatments to manage symptoms like fatigue, spasticity, or neuropathic pain, thus mitigating the risks associated with polypharmacy. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved